Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.

Efficacy A decreasing trend in ALT levels was observed from week 4 ( Figure 1A ), and the mean change in ALT levels from baseline to week 12 (primary end point) was −23.9 U/L (95% CI −48.1 to 0.3, P =0.0526) ( Table 2 ), corresponding to the percent change of −19.94% (95% CI −40.40 to 0.53).

also in 47,180 other papers